SBIR/STTR Research Award

A user-friendly microfluidic chip for anti-epileptogenic drug screening

Award identifier 6e60ba56f897801699ddf7c95db6a3ac15f143a0c465c78908e3e141530286e1Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$225,000

Program and phase

STTR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Xona Microfluidics, Inc.
Proposal award date
2018-09-01
Contract end date
2019-08-31
UEI
WKANFDSH6263
Solicitation number
PA17-303
Topic code
101

Research abstract

New pharmacological treatments for epilepsy will be discovered through the development of new screening platforms that are rapidreliableand can identify novel disease modifying therapiesor anti epileptogenic treatmentsXona MicrofluidicLLCXonais in a unique position to provide such screening tools and services for epilepsy researchXona focuses on the development of microfluidic platforms for neuron cell culture and provides devices that allow compartmentalization and fluidic isolation of axons and or dendritesand somataWe have patented technology and have sold devices to hundreds of labs world wideincluding many pharmaceutical laboratoriesEpileptogenesis induces an imbalance in inhibitory excitatory circuits within the brainleading to hyper excitability and seizuresA common cause of epilepsy is brain damage due to traumatic brain injury or strokeoften involving pyramidal cells within the hippocampusOur academic partners at UNC recently demonstrated the reliable induction of hyper excitability in pyramidal cells using a standard neuron deviceSNDconfiguration microfluidic chamber in response to axotomyNagendran et alNature CommunicationsThis hyper excitabilitywhich involves an imbalance of excitation and inhibitiondevelops reliably and with a delayat two days after axotomyIn separate NIH fundingwe dramatically improved the manufacturability of our platform leading to fully assembledmore robust devicesHere we will develop a new platform optimized for screening anti epileptogenic compounds to provide a much needed screening service to researchers as well as current and future pharmaceutical customersAimfocuses on developing a new injection moldable platform optimized to increase axon damage in a multi well formatAimwill lead to the development of an immunoassay to rapidly measure inhibitory excitatory balance within this microfluidic screening platform PUBLIC HEALTH RELEVANCEThis project will provide an important resource for the development of more effective epilepsy treatmentsKnowledge gained from this project has the potential to improve therapies and recovery outcomes for epilepsy

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

4 SBIR/STTR records share this UEI (2013–2022). Reported award amounts total $3,431,801. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.